Drug-screening in AML at Relapse for Targeted Treatment - Trial NCT05732688
Access comprehensive clinical trial information for NCT05732688 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital Inselspital, Berne and is currently Recruiting. The study focuses on AML. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University Hospital Inselspital, Berne
Timeline & Enrollment
N/A
Jan 01, 2022
Jun 01, 2024
Primary Outcome
Treatment with identified effective drug
Summary
This is a non-randomised clinical study investigating subsequent patients with specific AML
 treatment started between January 1, 2022 until December 31, 2022.
 
 Patients with relapsing disease are planned to be analyzed in this study
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05732688
Non-Device Trial